Lancet:他汀类药物在心血管事件一级预防中的作用无性别差异

2015-01-11 MedSci MedSci原创

研究背景: 他汀类药物治疗在女性中的心血管事件一级预防作用是否与男性一致,一直备受争议。研究人员在胆固醇治疗研究者协作组(Cholesterol Treatment Trialists' (CTT) Collaboration)数据库,对他汀类药物的临床试验进行了荟萃分析,即在于比较他汀类药物在男性和女性人群中的疗效。 研究方法: 研究人员供收集27项他汀类药物临床试验数据,其中

研究背景: 他汀类药物治疗在女性中的心血管事件一级预防作用是否与男性一致,一直备受争议。研究人员在胆固醇治疗研究者协作组(Cholesterol Treatment Trialists' (CTT) Collaboration)数据库,对他汀类药物的临床试验进行了荟萃分析,即在于比较他汀类药物在男性和女性人群中的疗效。 研究方法: 研究人员供收集27项他汀类药物临床试验数据,其中22项临床试验设有他汀类药物治疗组和安慰剂组(n=134 537),5项临床试验设有高强度的他汀类药物治疗组和低强度的他汀类药物治疗组(n=39 612)。研究人员采用非性别差异矫正的Cox回归模型,评估了每1.0 mmol/L的LDL胆固醇下降权重对重要的血管事件、重要的冠脉事件、中风、冠脉血流重建和死亡率的影响,并在男性和女性人群中评估药物疗效差异。对于亚组分析,研究人员采用99%可信区间进行多重比较。 研究结果: 随机招募的174149名受试者中,46675名(27%)为女性。在为期1年的血脂监测中,他汀类药物的疗效在男性和女性之间无差异(他汀类药物治疗组的LDL胆固醇浓度与安慰剂组相比下降1·1 mmo

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044361, encodeId=4647204436110, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun May 31 21:17:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643354, encodeId=f5b11643354d8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Jul 23 18:17:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827969, encodeId=8d12182e96953, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 31 11:17:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14277, encodeId=db83142e7cf, content=他汀仍然有一定保护作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.205.**, createdTime=Tue Jan 13 22:27:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14269, encodeId=a699142697a, content=有必要再按不同年龄段进行亚组分析, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lovetcm, createdTime=Tue Jan 13 21:50:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044361, encodeId=4647204436110, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun May 31 21:17:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643354, encodeId=f5b11643354d8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Jul 23 18:17:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827969, encodeId=8d12182e96953, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 31 11:17:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14277, encodeId=db83142e7cf, content=他汀仍然有一定保护作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.205.**, createdTime=Tue Jan 13 22:27:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14269, encodeId=a699142697a, content=有必要再按不同年龄段进行亚组分析, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lovetcm, createdTime=Tue Jan 13 21:50:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044361, encodeId=4647204436110, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun May 31 21:17:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643354, encodeId=f5b11643354d8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Jul 23 18:17:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827969, encodeId=8d12182e96953, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 31 11:17:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14277, encodeId=db83142e7cf, content=他汀仍然有一定保护作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.205.**, createdTime=Tue Jan 13 22:27:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14269, encodeId=a699142697a, content=有必要再按不同年龄段进行亚组分析, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lovetcm, createdTime=Tue Jan 13 21:50:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-01-31 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044361, encodeId=4647204436110, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun May 31 21:17:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643354, encodeId=f5b11643354d8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Jul 23 18:17:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827969, encodeId=8d12182e96953, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 31 11:17:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14277, encodeId=db83142e7cf, content=他汀仍然有一定保护作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.205.**, createdTime=Tue Jan 13 22:27:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14269, encodeId=a699142697a, content=有必要再按不同年龄段进行亚组分析, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lovetcm, createdTime=Tue Jan 13 21:50:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-01-13 175.9.205.**

    他汀仍然有一定保护作用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2044361, encodeId=4647204436110, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun May 31 21:17:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643354, encodeId=f5b11643354d8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Jul 23 18:17:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827969, encodeId=8d12182e96953, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 31 11:17:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14277, encodeId=db83142e7cf, content=他汀仍然有一定保护作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.205.**, createdTime=Tue Jan 13 22:27:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14269, encodeId=a699142697a, content=有必要再按不同年龄段进行亚组分析, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lovetcm, createdTime=Tue Jan 13 21:50:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-01-13 lovetcm

    有必要再按不同年龄段进行亚组分析

    0

相关资讯

Ann Intern Med:普通他汀或比著名品牌他汀药更佳

美国一项研究表明,与著名品牌他汀类相比,启用普通品牌的患者依从性更好,并且不良临床转归发生率更低。论文9月16日在线发表于《内科学年鉴》(Ann Intern Med)。 此项观察性研究共纳入90111例启用普通和注明品牌他汀类药物的65岁以上老年患者。评估他汀类治疗依从性,以及由急性冠脉综合征、卒中和全因死亡组成的复合转归。治疗依从性通过1年内覆盖天数比例(PDC)计算。 结果显

JAMA Inter Med:他汀不降低骨折风险(JUPITER预设分析)

12月1日在线发表于《美国医学会杂志 内科学》(JAMA: Internal Medicine)的JUPITER研究预设分析显示,他汀治疗不能预防骨折,且基线超敏C反应蛋白(hs-CRP)水平较高的患者骨折风险并未高于hs-CRP水平较低者。该研究的作者、美国纽约Albert Einstein医学院皮娜(Jessica Pe a)医生和同事声称该研究的结果不支持用降脂药降低患者骨折风险。

Lancet:他汀增加新发糖尿病的风险增加可能与HMGCR基因多态性有关

一项发表于2014年9月24日的《柳叶刀杂志》(Lancet)上的新研究表明他汀治疗确实和2型糖尿病风险显著升高有关,而导致这一现象的原因可能部分地归咎于编码β-羟-β-甲戊二酸单酰辅酶A(HMG-CoA)还原酶蛋白基因邻近基因变异。作者分析了 HMGCR基因、rs17238484 (用于主要分析)和 rs12916 (用于辅助分析),这些单核苷酸多态性是他汀类药物抑制 HMGCR 主要靶标。

郭艺芳点评:强效降胆固醇:大剂量他汀还是常规剂量他汀联合依折麦布?(IMPROVE-IT研究)

2014年AHA年会期间揭晓了IMPROVE-IT研究结果。近年来,此研究一直受到广泛期待。之所以如此,是因为这项研究或可回答两个至关重要的问题:(1)降胆固醇是硬道理还是他汀是硬道理?已有充分证据显示,应用他汀降低胆固醇水平可以显著降低心血管病患者及其高危人群不良心血管事件的发生率。但应用其他药物降低胆固醇水平是否产生同样的获益尚不清楚。(2)当LDL-C处于较低水平时继续降低其水平可否进一步获